Mitiglinide - Kissei Pharmaceutical
Alternative Names: Glinsuna; Glufast; KAD-1229; Kuai ruo tuo; S 21403Latest Information Update: 05 Nov 2023
At a glance
- Originator Kissei Pharmaceutical
- Developer Aichi Gakuin University; Eisai Co Ltd; Elixir Pharmaceuticals; Hikma Pharmaceuticals; JW Pharmaceutical; Kissei Pharmaceutical; Orient Europharma; Takeda; USV
- Class Amides; Antihyperglycaemics; Butyric acids; Isoindoles; Small molecules
- Mechanism of Action Insulinotropin agonists; Peroxisome proliferator-activated receptor gamma agonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 06 Aug 2019 Launched for Type 2 diabetes mellitus in Taiwan before August 2019 (PO)
- 06 Aug 2019 Preregistration for Type 2 diabetes mellitus in Vietnam (PO) before August 2019 (Kissei Pharmaceutical pipeline August 2019)
- 06 Aug 2019 Registered for Type 2 diabetes mellitus in Laos (PO) before August 2019 (Kissei Pharmaceutical pipeline August 2019)